Af­ter safe­ty re­view, EMA mir­rors FDA with up­dat­ed rec­om­men­da­tions for JAK in­hibitors

The EMA re­leased up­dat­ed rec­om­men­da­tions to­day for the use of JAK in­hibitors (JA­Ki) af­ter re­view­ing da­ta from sev­er­al clin­i­cal tri­als that showed in­creased in­ci­dents of is­sues in cer­tain pa­tients who have rheuma­toid arthri­tis and oth­er risk fac­tors.

The EMA not­ed ma­lig­nan­cy, ma­jor ad­verse car­dio­vas­cu­lar events (MACE), se­ri­ous in­fec­tions, ve­nous throm­boem­bolism (VTE) and mor­tal­i­ty in some pa­tients.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN